CJC-1295 For Sale — Research Grade
PX1 Research supplies USA-synthesized, high-purity CJC-1295 for sale to academic institutions, biotechnology facilities, and qualified laboratory researchers. Every lot undergoes rigorous HPLC and Mass Spectrometry validation to guarantee exceptional structural integrity, batch consistency, and low endotoxin levels for in vitro and animal models. All orders ship same-day Monday through Friday from our California and Arizona fulfillment centers.
Quick answer
PX1 Research supplies USA-synthesized, high-purity CJC-1295 for sale to academic institutions, biotechnology facilities, and qualified laboratory researchers. Every lot undergoes rigorous HPLC and Mass Spectrometry validation to guarantee exceptional structural integrity, batch consistency, and low endotoxin levels for in vitro and animal models. All orders ship same-day Monday through Friday from our California and Arizona fulfillment centers.
Key takeaways
- In biomedical research, sourcing high-purity peptides with reliable analytical verification is crucial for obtaining reproducible data.
- [CJC-1295](/research-peptides/cjc-1295-no-dac) was engineered through rational sequence modification of the N-terminal 29-amino-acid sequence of human GHRH.
- [CJC-1295](/research-peptides/cjc-1295-no-dac) functions as a selective agonist at the growth hormone-releasing hormone receptor (GHRHR), a G-protein coupled receptor expressed prominently on anterior pituitary somatotropes.
- Laboratory researchers must distinguish between [CJC-1295](/research-peptides/cjc-1295-no-dac) with DAC and CJC-1295 without DAC (frequently designated as Modified GRF 1-29).
High-Purity CJC-1295 for Laboratory Applications
In biomedical research, sourcing high-purity peptides with reliable analytical verification is crucial for obtaining reproducible data. CJC-1295 is a synthetic 29-amino-acid peptide derivative of growth hormone-releasing hormone (GHRH). Designed to overcome the rapid enzymatic degradation characteristic of endogenous native GHRH (1-29), CJC-1295 provides researchers with a stabilized molecular tool to examine somatotrophic axis dynamics and downstream metabolic pathways.
When purchasing CJC-1295 for sale, research teams require verifiable purity profiles free of TFA counterion excess, truncated peptide sequences, or microbial contaminants. PX1 Research manufactures all research compounds within USA-based, GMP-compliant facilities. Each batch undergoes independent quality testing in an ISO 17025 accredited laboratory, ensuring that experimental models receive standardized, reliable materials.
Molecular Structure and Bioconjugation Mechanics
CJC-1295 was engineered through rational sequence modification of the N-terminal 29-amino-acid sequence of human GHRH. Endogenous GHRH(1-29) NH2 is rapidly cleaved by dipeptidyl peptidase IV (DPP-IV) between the Alanine-2 and Aspartate-3 residues, resulting in a systemic elimination half-life of fewer than 12 minutes in rodent and mammalian models. To prevent rapid enzymatic cleavage, CJC-1295 incorporates specific amino acid substitutions: D-Alanine at position 2, Glutamine at position 8, Alanine at position 15, and Leucine at position 27.
In its modified form—often referred to as CJC-1295 with Drug Affinity Complex (DAC)—a reactive maleimidopropionic acid linker is covalently attached to the Lysine residue at position 30. In vitro data indicate that this reactive group undergoes selective bioconjugation with free thiols on circulating serum albumin (specifically at Cys-34). This covalent albumin binding insulates the peptide structure against renal clearance and proteolysis, extending the half-life significantly during preclinical research protocols.
Mechanism of Action: GHRH Receptor Agonism
CJC-1295 functions as a selective agonist at the growth hormone-releasing hormone receptor (GHRHR), a G-protein coupled receptor expressed prominently on anterior pituitary somatotropes. Receptor activation initiates a signal transduction cascade that stimulates adenylyl cyclase, elevating intracellular cyclic adenosine monophosphate (cAMP) and activating protein kinase A (PKA).
Preclinical studies suggest that this signaling cascade triggers the transcription of growth hormone (GH) mRNA and facilitates extracellular exocytosis of GH storage vesicles. Unlike direct GH administration, GHRHR agonism preserves endogenous physiological feedback loops, permitting somatostatin-mediated inhibition to modulate extreme secretagogue surges. Investigating these regulatory feedback dynamics remains a core focus of current growth hormone-releasing hormone (GHRH) analogs research.
Comparative Analysis: CJC-1295 With DAC vs. No DAC
Laboratory researchers must distinguish between CJC-1295 with DAC and CJC-1295 without DAC (frequently designated as Modified GRF 1-29). While both constructs utilize identical amino acid substitutions to resist DPP-IV degradation, the omission of the reactive linker in Modified GRF 1-29 prevents irreversible albumin bioconjugation.
In animal models, CJC-1295 without DAC exhibits a terminal half-life of approximately 30 minutes, producing discrete, transient GH peaks that closely mimic baseline physiological pulses. Conversely, CJC-1295 with DAC exhibits an extended biological half-life exceeding 6 to 8 days due to continuous systemic circulation while bound to serum proteins. Selecting between these two variants depends heavily on whether an experimental assay requires discrete, pulsatile signaling or sustained basal elevation of GH and downstream markers.
Preclinical Applications in Tissue Repair and Metabolic Research
Because CJC-1295 sustainedly elevates systemic GH secretion, preclinical research consistently focuses on the downstream hepatic synthesis of insulin-like growth factor 1 (IGF-1). In vitro assay models and animal studies suggest that elevated IGF-1 concentrations play a central role in cellular proliferation, myoblast differentiation, and extracellular matrix remodeling.
Investigators utilize CJC-1295 to evaluate tissue repair dynamics in musculoskeletal defect models. Preclinical studies suggest that sustained GHRH signaling promotes collagen synthesis within tenocytes and osteoblasts, accelerating connective tissue remodeling following artificial lesioning. Additionally, rodent metabolic studies examine how prolonged GH pulse amplitude elevation influences lipid mobilization, hepatic gluconeogenesis, and nitrogen retention during catabolic states.
Secretagogue Class Comparison: GHRH vs. GHRP Systems
To maximize secretagogue activity in experimental models, research teams frequently evaluate GHRH analogs alongside growth hormone secretagogue receptor (GHSR) agonists. Comparing mechanisms across these peptide classes provides vital context for experimental design:
When evaluating secretagogue mechanics, researchers often combine a GHRH agonist like CJC-1295 with DAC or Sermorelin with a selective ghrelin receptor agonist such as Ipamorelin. In vitro data indicate that simultaneous activation of GHRHR and GHSR produces a synergistic elevation of GH secretion far greater than the additive effect of either compound administered alone. Alternative GHRH constructs like Tesamorelin offer tailored activity profiles specifically validated in metabolic lipid research models. For broader experimental contextualization, researchers can consult our comprehensive peptide research library.
Analytical Quality Control: HPLC, MS, and Endotoxin Standards
At PX1 Research, quality assurance is an absolute priority. To ensure optimal performance in cell culture and animal models, every batch of CJC-1295 undergoes rigorous analytical verification prior to release. Our multi-stage testing protocol includes:
High-Performance Liquid Chromatography (HPLC) to verify chemical purity exceeds 98.0%, eliminating truncated peptidic impurities. Mass Spectrometry (MS) confirms exact molecular mass and sequence identity, ruling out unintended amino acid substitutions. Additionally, Limulus Amebocyte Lysate (LAL) testing guarantees endotoxin limits remain strictly under 0.01 EU/mg, preventing inflammatory interference during sensitive cell assays or in vivo studies.
Laboratory Reconstitution and Storage Protocols
CJC-1295 is supplied as a lyophilized (freeze-dried) powder under inert argon gas atmosphere to ensure maximum shelf-life stability. Unopened vials should be stored at -20°C for long-term storage, protected from light and moisture exposure.
For laboratory reconstitution, researchers should utilize sterile bacteriostatic water or standard phosphate-buffered saline (PBS) depending on assay requirements. Solvent should be added down the inner glass wall of the vial, followed by gentle swirl agitation. Direct high-shear vortexing must be avoided to prevent protein denaturation or aggregation. Once reconstituted, solutions remain stable at 2°C to 8°C for short-term evaluation, or should be aliquoted and stored at -80°C to prevent freeze-thaw degradation cycles. Institutional labs seeking bulk volume requirements can submit inquiries via our bulk laboratory accounts portal.
USA Manufacturing and Same-Day Dispatch Infrastructure
PX1 Research operates dedicated dispatch nodes in California and Arizona, allowing fast, climate-controlled logistics for research facilities across the United States. Orders confirmed before 3:00 PM EST Monday through Friday are processed and dispatched same-day.
Lyophilized CJC-1295 maintains high chemical stability during transit under ambient temperatures. Every order is packed in heavy-duty, protective enclosure materials with lot-specific documentation. Investigators can scan the physical QR code on product labeling to instantly access the lot-matched Certificate of Analysis (COA) directly from their laboratory workstation.
Frequently Asked Questions
What is the certified chemical purity of CJC-1295 from PX1 Research?
Every lot of CJC-1295 offered for sale undergoes reverse-phase HPLC and Mass Spectrometry analysis to guarantee a chemical purity threshold of equal to or greater than 98.0%.
How does CJC-1295 with DAC differ from Modified GRF 1-29?
CJC-1295 with DAC includes a maleimidopropionic acid linker covalently bound to Lysine-30, allowing bioconjugation to serum albumin and extending its biological half-life to several days. Modified GRF 1-29 lacks this linker, resulting in a half-life of approximately 30 minutes.
What are the verified endotoxin levels in PX1 Research peptides?
All research-grade peptides from PX1 Research undergo strict LAL assay testing to confirm endotoxin concentrations remain below 0.01 EU/mg, preventing endotoxin-induced cell toxicity or systemic non-specific inflammatory responses.
What solvent is recommended for reconstituting lyophilized CJC-1295?
For standard laboratory use, reconstitute lyophilized CJC-1295 using sterile bacteriostatic water (0.9% benzyl alcohol) or sterile laboratory-grade saline/PBS, depending on the requirements of your specific assay model.
How quickly do CJC-1295 orders ship?
All orders placed before 3:00 PM EST, Monday through Friday, ship the same day from our fulfillment facilities located in California and Arizona.
How should reconstituted CJC-1295 be stored in the laboratory?
Reconstituted liquid CJC-1295 solutions should be stored at 2°C to 8°C for short-term experimentation (up to 30 days if prepared with bacteriostatic water). For longer storage, solutions should be sub-aliquoted and kept at -80°C to minimize freeze-thaw cycles.
Can I obtain bulk quantities of CJC-1295 for large institutional trials?
Yes, PX1 Research provides institutional tiering and custom batch sizing for high-volume scientific trials through our bulk laboratory accounts division.
Is CJC-1295 approved for clinical or human consumption?
No. CJC-1295 supplied by PX1 Research is exclusively manufactured and distributed as a research compound intended strictly for laboratory in vitro and preclinical research applications.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.